Drug discovery

How Might Biomolecular Condensates Revolutionize Drug Discovery? A Perspective from Dewpoint Therapeutics

Retrieved on: 
Wednesday, August 17, 2022 - 11:59pm

BOSTON, Aug. 17, 2022 /PRNewswire/ -- A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery.

Key Points: 
  • BOSTON, Aug. 17, 2022 /PRNewswire/ -- A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery.
  • In "Modulating biomolecular condensates: a novel approach to drug discovery," a Dewpoint Therapeutics perspective, the authors discuss the largely untapped opportunities for targeting biomolecular condensates to develop therapeutic agents for various diseases.
  • Condensate-targeted drug discovery was pioneered by Dewpoint Therapeutics as the firstbiotech company to enter the field, founded in 2018.
  • Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery.

Exscientia Business Update for Second Quarter and First Half 2022

Retrieved on: 
Wednesday, August 17, 2022 - 9:01pm

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220817005681/en/
    Recent developments in the Companys pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below.
  • In addition, Exscientia will host a conference call Thursday, August 18 at 1:30 p.m. BST / 8:30 a.m.
  • In the first half of 2022, we delivered on major new and existing collaborations, advanced our pipeline programmes, and marked the 10-year anniversary of Exscientias founding.
  • A replay will be available for 90 days under "Events and Presentations in the Investors and Media section of the Exscientia website .

Syntekabio Presents Innovative AI Drug Discovery Cloud Platforms DeepMatcher® and NEO-ARS™ at UKC 2022

Retrieved on: 
Wednesday, August 17, 2022 - 3:46pm

ARLINGTON, Va., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Global AI drug discovery and development company Syntekabio will present its innovative and efficient proprietary AI-based drug discovery cloud platforms DeepMatcher and NEO-ARS, scheduled to launch this September, on Aug. 19 at the US-Korea Conference (UKC) in Arlington, Virginia.

Key Points: 
  • ARLINGTON, Va., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Global AI drug discovery and development company Syntekabio will present its innovative and efficient proprietary AI-based drug discovery cloud platforms DeepMatcher and NEO-ARS, scheduled to launch this September, on Aug. 19 at the US-Korea Conference (UKC) in Arlington, Virginia.
  • The Innovative and Entrepreneurship Symposium (IES) enables participating companies with promising products and technologies to present their insights and ideas for growing cross-border business opportunities in the U.S. and Korea.
  • WHO: Kilyoung Kim, PhD, CSO and president of Syntekabio USA, will introduce the company and present its latest technology in AI drug discovery and development at the symposium.
  • For Syntekabio's products and services, visit http://www.syntekabio.com/eng/ or contact the New York office at admin.usa@syntekabio.com or +1 (212) 371-2544.

The Worldwide Artificial Intelligence for Drug Discovery and Development Industry is Expected to Reach $4.8 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022 - 3:32pm

The Global Artificial Intelligence for Drug Discovery and Development Market is estimated to be USD 1.22 Bn in 2022 and is expected to reach USD 4.8 Bn by 2027, growing at a CAGR of 31.54%.

Key Points: 
  • The Global Artificial Intelligence for Drug Discovery and Development Market is estimated to be USD 1.22 Bn in 2022 and is expected to reach USD 4.8 Bn by 2027, growing at a CAGR of 31.54%.
  • The report presents a detailed Ansoff matrix analysis for the Global Artificial Intelligence for Drug Discovery and Development Market.
  • The analyst analyses the Global Artificial Intelligence for Drug Discovery and Development Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Artificial Intelligence for Drug Discovery and Development Market.

Emery Pharma Announces New Biologics Analytical Division

Retrieved on: 
Wednesday, August 17, 2022 - 1:00pm

ALAMEDA, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Emery Pharma has officially expanded its state-of-the-art laboratories which feature a brand-new High-Resolution Orbitrap Mass Spectrometer, enabling Emery Pharma to expand its service offerings.

Key Points: 
  • ALAMEDA, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Emery Pharma has officially expanded its state-of-the-art laboratories which feature a brand-new High-Resolution Orbitrap Mass Spectrometer, enabling Emery Pharma to expand its service offerings.
  • We are excited for him to lead the new Large Molecule Analytical Division at Emery Pharma," said Dr. Neel Bose, CSO.
  • Emery Pharma is a full-service contract research laboratory, specializing in supporting preclinical drug development, including analytical, bioanalytical solutions, microbiology & cell biology services, drug and impurity characterization, and general R&D and cGMP/GLP support.
  • Emery Pharma is equipped to support the development of small molecule drugs, biologics, biosimilars, gene therapies, botanical drugs, and more.

Mytide Therapeutics Partners with Agilent to Collaborate on Automation Solutions for Mytide’s Next-generation Manufacturing Platform

Retrieved on: 
Wednesday, August 17, 2022 - 1:00pm

The two companies will collaborate on robust, scalable and reliable automation solutions for Mytides BioFab2 platform, a technology suite that combines chemistry, robotics and machine learning to advance and accelerate peptide and peptide conjugate manufacturing.

Key Points: 
  • The two companies will collaborate on robust, scalable and reliable automation solutions for Mytides BioFab2 platform, a technology suite that combines chemistry, robotics and machine learning to advance and accelerate peptide and peptide conjugate manufacturing.
  • Under the terms of the agreement, Agilent will supply analytical and preparative chromatography equipment for Mytides BioFab2 fleet.
  • Agilent is very excited by the opportunity to collaborate with the pioneering team at Mytide Therapeutics.
  • Mytides BioFab2 platform is designed to be integrated into cGMP manufacturing environments to allow for scalable and decentralized clinical trial manufacturing of a partners lead peptide-based therapeutic candidate.

Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery

Retrieved on: 
Wednesday, August 17, 2022 - 1:00pm

Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will leverage its AtomNet platform for computational discovery and research of up to five drug targets.

Key Points: 
  • Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will leverage its AtomNet platform for computational discovery and research of up to five drug targets.
  • The Atomwise approach shifts the mode of drug discovery away from serendipitous discovery and toward search based on structure, making the drug discovery process more rational, effective, and efficient.
  • At Sanofi, we are committed to bringing higher quality medicines to patients faster, empowered by our advanced AI drug discovery engine.
  • Together, we aim at making the drug discovery process more efficient and effective in particular when very limited information is available to support drug design.

Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia

Retrieved on: 
Wednesday, August 17, 2022 - 12:00pm

The Companys innovatively-assembled and proprietary rose bengal is the lead member of a class of small molecules called halogenated xanthenes.

Key Points: 
  • The Companys innovatively-assembled and proprietary rose bengal is the lead member of a class of small molecules called halogenated xanthenes.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes (HXs).
  • Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements.
  • Risks, uncertainties, and assumptions include those discussed in the Companys filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:

EIB to Support Ryvu Therapeutics’ Discovery, Research and Development of New Cancer Treatments with €22 Million

Retrieved on: 
Wednesday, August 17, 2022 - 7:10am

The EIBs support will help Ryvu finance its development pipeline of new cancer treatments from discovery through to clinical trials.

Key Points: 
  • The EIBs support will help Ryvu finance its development pipeline of new cancer treatments from discovery through to clinical trials.
  • The EIBs investment will strengthen Ryvu Therapeutics research, development and innovation capacity and competitiveness for the wider social benefit.
  • Innovation, research, digital economy and the development of human capital are top priorities for the EIB Group.
  • The additional funding will go towards the discovery, research and development of innovative therapeutics to treat cancer patients.

SRI International Launches Commercialization Group, Announces New President

Retrieved on: 
Tuesday, August 16, 2022 - 5:22pm

MENLO PARK, Calif., Aug. 16, 2022 /PRNewswire/ -- SRI International, an independent non-profit research institute, today announced the launch of its expanded commercialization group, led by incoming President, Commercialization, Suresh Sunderrajan. This new group will integrate and scale SRI's efforts to bring innovations to market through ventures, technology productization and licensing, corporate partnerships and innovation consulting.

Key Points: 
  • MENLO PARK, Calif., Aug. 16, 2022 /PRNewswire/ -- SRI International , an independent non-profit research institute, today announced the launch of its expanded commercialization group, led by incoming President, Commercialization, Suresh Sunderrajan.
  • "Suresh's leadership will be pivotal in implementing SRI's strategy to translate its pioneering research into world-changing solutions," said SRI CEO, David Parekh.
  • "This strategic focus will enable SRI to make an even greater impact beyond its fundamental scientific discoveries and early-stage innovations."
  • SRI, a research center headquartered in Menlo Park, California, works primarily in advanced technology and systems, biosciences, computing and education.